Erin Delker

Erin Delker

Auto-generated profile, based on publicly available information

Erin Delker

Department of Pediatrics University of California San Diego San Diego California USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in The Journal of Pediatrics
Verified
Journal Article
Closed access
SGSheila Gahagan
Sheila Gahagan
EDErin Delker
Erin Delker
EBEstela Blanco
Estela Blanco
RBRaquel Burrows
Raquel Burrows
BLBetsy Lozoff
Betsy Lozoff

21 July 2021 in Psychosomatic Medicine
Verified
Journal Article
Closed access
EDErin Delker
Erin Delker
BABandar MBBS AlYami
Bandar MBBS AlYami
LGLinda C. Gallo
Linda C. Gallo
JRJohn M. Ruiz
John M. Ruiz
MSMoyses MD Szklo
Moyses MD Szklo
MAMatthew A. Allison
Matthew A. Allison
Objective: We investigated the role of chronic stress burden on adiposity and adiposity-related inflammation with two hypotheses: a) greater chronic stress is associated with higher central adiposity and selective accumulation of visceral adipose tissue (VAT) compared with subcutaneous adipose tissue (SAT), and b) associations between VAT and inflammatory biomarkers are exacerbated when chronic stress is high. Methods: Data come from 1809 participants included in a Multi-Ethnic Study of Atherosclerosis ancillary study of body composition and adiposity-related inflammation. Chronic psychosocial stress was measured with a five-item version of the Chronic Stress Burden Scale. First, we tested associations between chronic stress (three-level categorical variable) and VAT, SAT, and VAT/SAT ratio. Second, we tested whether associations between VAT and inflammatory biomarkers varied by level of chronic stress. Results: Participants were approximately 65 years, 50% female, and 40.5% White, 25.6% Hispanic, 21.2% African American, and 12.8% Chinese American. About half of the sample reported little to no stress, and a quarter and a fifth of the sample reported medium and high levels of stress. Higher levels of chronic stress were associated with greater VAT and SAT, but not VAT/SAT ratio. Greater levels of VAT were associated with increased levels of adiposity-related inflammation in a graded pattern. These associations did not vary by stress level. Conclusions: Greater chronic stress burden is associated with both central and subcutaneous adiposity. We found no evidence that the associations between VAT and inflammatory biomarkers are exacerbated by chronic stress. Findings contribute to ongoing literature untangling pathways in which psychosocial stress contributes to adiposity-related inflammation.

5 July 2023 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
EDErin Delker
Erin Delker
SHShana Bs Hayes
Shana Bs Hayes
AKAnn E. Kelly
Ann E. Kelly
KJKenneth L. Jones
Kenneth L. Jones
CCChristina Chambers
Christina Chambers
GBGretchen Bandoli
Gretchen Bandoli
OBJECTIVE: To review and perform a meta-analysis of observational studies that examined associations between prenatal cannabis exposure and major structural birth defects. DATA SOURCES: Information sources included Google Scholar, BIOSIS, PubMed/MEDLINE, EMBASE CINAHL, and ClinicalTrials.gov. METHODS OF STUDY SELECTION: Study titles and abstracts were reviewed with Abstrackr software. We included observational studies that examined the risk of major structural birth defects in people who used cannabis during pregnancy compared with those who had not used cannabis. We excluded case reports, ecologic studies, conference abstracts, manuscript preprints, studies designed to examine effects of cannabis used concurrently with other drugs, and studies that included synthetic cannabinoids. This process yielded 23 studies that analyzed data from birth years 1968–2021. TABULATION, INTEGRATION, AND RESULTS: We clustered and meta-analyzed measures of association for birth defects by anatomic group. Eleven articles reported an association between cannabis use and the risk of a nonspecific outcome (eg, congenital anomaly). We estimated a pooled odds ratio of 1.33 (95% CI 1.14–1.56) and a pooled adjusted odds ratio (aOR) of 1.22 (95% CI 1.00–1.50). Anatomic groups examined were cardiac (nine studies), oral cleft (three studies), digestive (four studies), genitourinary (three studies), musculoskeletal (seven studies), and nervous system (five studies). Across most outcomes, we reported positive pooled unadjusted associations that were usually attenuated after the inclusion of only adjusted estimates. Two specific anomalies, with limited data, had pooled effect estimates that did not attenuate to the null after adjustment: Ebstein anomaly (two studies, aOR 2.19, 95% CI 1.25–3.82) and gastroschisis (five studies, aOR 2.50, 95% CI 1.09–5.740). CONCLUSION: Studies examining associations between prenatal exposure to cannabis and major structural birth defects were heterogeneous. Most published effect estimates were unadjusted and scored low on our risk-of-bias assessment. Overall, we found inconsistent evidence to suggest that prenatal cannabis exposure is associated with birth defects. However, findings related to specific anomalies should be considered in further research. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42022319041.

2 February 2022 in Paediatric and Perinatal Epidemiology
Verified
Journal Article
Closed access
PDF file
EDErin Delker
Erin Delker
GBGretchen Bandoli
Gretchen Bandoli
YLYvette LaCoursiere
Yvette LaCoursiere
KFKaren Ferran
Karen Ferran
LGLinda Gallo
Linda Gallo
MAMatthew Allison
Matthew Allison

9 December 2022 in Drug and Alcohol Dependence
Verified
Journal Article
Open access
GBGretchen Bandoli
Gretchen Bandoli
EDErin Delker
Erin Delker
BSBenjamin T. Schumacher
Benjamin T. Schumacher
RBRebecca J. Baer
Rebecca J. Baer
AKAnn E. Kelly
Ann E. Kelly
CCChristina D. Chambers
Christina D. Chambers
To determine whether maternal cannabis use disorder is associated with infant hospitalization or death in the first year of life. We queried an administrative birth cohort derived from the hospital discharge database maintained by the California Office of Statewide Health Planning and Development and linked with vital statistics files. We included singleton, live-birth deliveries between 2011 and 2018. Pregnancies with cannabis use disorder were classified from International Classification of Disease codes. Outcomes included infant emergency department visits and hospital admissions identified from health records, and infant deaths identified from death records. Models were adjusted for sociodemographic variables, psychiatric comorbidities and other substance use disorders. There were 34,544 births (1.0 %) with a cannabis use disorder diagnosis in pregnancy, with increasing prevalence over the study period. The incidence of infant death in the first year of life was greater among those with a maternal cannabis use disorder diagnosis than those without (1.0 % vs 0.4 %; adjusted risk ratio 1.4 95 % CI: 1.2-1.6). When examining specific causes of death, the increased risk estimates were attributable to perinatal conditions and sudden unexpected infant death. After adjustment, there was no increased risk of infant hospitalizations or emergency department visits. These findings warrant further investigation into the underlying mechanisms of maternal prenatal CUD on infant outcomes, and add to a rapidly expanding body of literature supporting the need for effective treatment options for pregnant individuals with cannabis use disorders.

1 August 2020 in Journal of Prevention
Verified
Journal Article
Closed access
PDF file
EDErin Delker
Erin Delker
PEPatricia East
Patricia East
EBEstela Blanco
Estela Blanco
VWVictoria Wu
Victoria Wu
PEPamela Encina
Pamela Encina
SGSheila Gahagan
Sheila Gahagan